SIREN : 812620094
PHARMADVIZ is a French company founded 10 years ago, specialized in the sector Conseil en systèmes et logiciels informatiques. Based in PARIS (75008), this company of category PME shows in 2024 a revenue of 899 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 898 734 € | 670 930 € | 507 322 € | 591 934 € | 592 790 € | 432 215 € | 982 022 € |
| Net income | 10 875 € | 16 597 € | 12 246 € | 19 397 € | 15 083 € | 16 936 € | 30 843 € |
| EBITDA | 17 447 € | 22 776 € | 16 051 € | 25 881 € | 20 995 € | 22 204 € | 36 290 € |
| Net margin | 1.2% | 2.5% | 2.4% | 3.3% | 2.5% | 3.9% | 3.1% |
In 2024, PHARMADVIZ achieves revenue of 899 k€. Activity remains stable over the period (CAGR: -1.1%). Vs 2021, growth of +34% (671 k€ -> 899 k€). After deducting consumption (0 €), gross margin stands at 899 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 17 k€, representing 1.9% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 11 k€, i.e. 1.2% of revenue. This profit can be retained or distributed to shareholders.
898 734 €
898 734 €
17 447 €
15 228 €
10 875 €
1.9%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 42%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 1.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
0.0%
42.029%
1.457%
0.0
23.2%
In 2024, the debt ratio of PHARMADVIZ (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of PHARMADVIZ (42.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of PHARMADVIZ (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 202.96. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 4.1x. Financial charges are adequately covered by operations.
202.958
4.092
In 2024, the liquidity ratio of PHARMADVIZ (202.96) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of PHARMADVIZ (4.1x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 78 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 73 days. The company must finance 5 days of gap between collections and payments. Overall, WCR represents 59 days of revenue, i.e. 147 k€ to permanently finance. Over 2016-2024, WCR increased by +2224%, requiring additional financing.
147 419 €
78 j
73 j
0 j
59 j
Based on 215 transactions of similar company sales (all years), the value of PHARMADVIZ is estimated at 55 006 € (range 27 818€ - 126 123€). With an EBITDA of 17 447€, the sector multiple of 1.0x is applied. The price/revenue ratio is 0.16x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 215 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMADVIZ with other companies in the same sector:
Voir toutes les statistiques du secteur Conseil en systèmes et logiciels informatiques
The revenue of PHARMADVIZ in 2024 is 899 k€.
Yes, PHARMADVIZ generated a net profit of 11 k€ in 2024.
The headquarters of PHARMADVIZ is located in PARIS (75008), in the department Paris.
The tax return of PHARMADVIZ is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMADVIZ operates in the sector Conseil en systèmes et logiciels informatiques (NAF code 62.02A). See the 'Sector positioning' section above to compare the company with its competitors.